ArticleFrontiers in immunology2026
Gegen Qinlian decoction alleviates DSS-induced colitis in mice through coordinated modulation of gut microbiota, serum metabolome, and colonic γδT cell responses.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gegen Qinlian Decoction, a classic traditional Chinese medicine formula: a potential therapeutic strategy for ulcerative colitis and colorectal cancer.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease. Despite advances in current therapies, safer, more effective drugs are urgently needed. Traditional Chinese herbal formula Gegen Qinlian Decoction (GQD) has been used for gastrointestinal disorders, including UC, though its exact mechanisms require further clarification. Objective: This study aimed to systematically evaluate the therapeutic effects of GQD in UC mice, focusing on serum metabolomics, gut microbiota, and immunomodulatory mechanisms. Methods: A dextran sulfate sodium (DSS)-induced mouse model of UC was established. Serum metabolomics and 16S rRNA sequencing analysis of GQD's effects on metabolites and gut microbiota. Correlation analysis and network pharmacology identified potential targets and pathways of GQD. Immunofluorescence detected the expression of γδT cells, TNF-α, IFN-γ, and IL-17 proteins in the colonic tissue. Results: Using UPLC-QE-Orbitrap-MS, 71 compounds were identified in the GQD quality control analysis. GQD markedly attenuated colonic histopathological damage and suppressed serum pro-inflammatory cytokines IFN-γ, IL-17, and TNF-α. It also modulated key serum metabolites, including succinic acid, glyoxylate, and xanthine, which are primarily involved in amino acid and purine metabolic pathways. GQD further influenced intestinal microbial diversity and composition. Joint analysis revealed GQD modulates gut microbiota, serum amino acid and purine metabolism, and inflammation pathways. Immunohistochemical results demonstrated enhanced infiltration of γδT cells following GQD treatment, accompanied by reduced protein expression levels of TNF-α, IFN-γ, and IL-17. Conclusion: GQD exerts therapeutic effects on UC by reshaping gut microbiota composition and metabolic activities, thereby ameliorating intestinal mucosal injury, regulating γδT cell-mediated immune responses, and influencing amino acid and purine metabolic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.